/ELVN
ELVN Stock - Enliven Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$16.87+1.14%
+$0.19 (+1.14%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+169.7%upside
Target: $45.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.70 – $17.04
TARGET (TP)$45.50
STOP LOSS$15.52
RISK/REWARD1:21.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.07
52W High$25.37
52W Low$13.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-104,554,000 | $-83,529,000 | $-38,791,000 | $-24,762,000 | $-9,318,000 |
| Net Income | $-89,024,000 | $-71,584,000 | $-37,662,000 | $-24,740,000 | $-18,966,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.89 | $-2.01 | $-6.03 | $-3.17 | $-4.31 |
Company Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$35
Average Target
↑ 106.5% Upside
Now
$27
Low
$35
Average
$42
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 16th 2025 | Goldman | Initiation | Buy | $37 |
| December 13th 2024 | BTIG Research | Initiation | Buy | $42 |
| September 9th 2024 | H.C. Wainwright | Initiation | Buy | $37 |
| June 11th 2024 | Robert W. Baird | Initiation | Outperform | $32 |
| April 9th 2024 | Mizuho | Initiation | Buy | $34 |
| March 29th 2023 | Jefferies | Initiation | Buy | $27 |
| March 3rd 2023 | TD Cowen | Initiation | Outperform | - |
Earnings History & Surprises
ELVNBeat Rate
78%
Last 18 quarters
Avg Surprise
+24.6%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
+16.1%
$-0.47vs$-0.56
Q2 24
+6.9%
$-0.54vs$-0.58
Q3 24
+29.3%
$-0.41vs$-0.58
Q4 24
+7.7%
$-0.48vs$-0.52
Q1 25
+13.2%
$-0.46vs$-0.53
Q2 25
-11.8%
$-0.57vs$-0.51
Q3 25
+7.5%
$-0.49vs$-0.53
Q4 25
+25.6%
$-0.32vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.42 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.43 | $-0.32 | +25.6% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.53 | $-0.49 | +7.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.51 | $-0.57 | -11.8% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.53 | $-0.46 | +13.2% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.58 | $-0.41 | +29.3% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.58 | $-0.54 | +6.9% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.56 | $-0.47 | +16.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.49 | $-0.51 | -4.1% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.40 | $-0.41 | -2.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.67 | $-0.80 | -19.4% | ✗ MISS |
Q1 2023 | Feb 10, 2023 | $-0.79 | $1.23 | +256.5% | ✓ BEAT |
Q4 2022 | Oct 25, 2022 | $-1.00 | $-0.72 | +28.0% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-2.05 | $-1.76 | +14.1% | ✓ BEAT |
Q2 2022 | May 6, 2022 | $-2.31 | $-2.24 | +3.0% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-3.00 | $-2.12 | +29.3% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-3.38 | $-2.20 | +34.9% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $-3.20 | $-2.96 | +7.5% | ✓ BEAT |
Latest News
Enliven Therapeutics Appoints Rick Fair As CEO And Member Of Board Of Directors, Effective Immediately
➖ NeutralBenzinga•Dec 11, 2025, 02:04 PM
Enliven Therapeutics Q3 EPS $(0.32) Beats $(0.45) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:43 PM
Enliven Therapeutics shares are trading lower. The company announced it will present data from the ongoing ENABLE Phase 1a/1b clinical trial of ELVN-001 on a subset of chronic myeloid leukemia patients, specifically in patients with atypical fusion transcripts, at the 67th Annual American Society of Hematology 2025 Annual Meeting and Exposition.
➖ NeutralBenzinga•Nov 3, 2025, 05:33 PM
Enliven's ELVN-001 Shows Anti-CML Activity In Patients With Atypical Fusion Transcripts; Will Present Data From The Ongoing ENABLE Phase 1a/1b Clinical Trial Of ELVN-001 On A Subset Of Chronic Myeloid LeukemiaPatients At The ASH 2025 Annual Meeting
📈 PositiveBenzinga•Nov 3, 2025, 02:09 PM
Frequently Asked Questions about ELVN
What is ELVN's current stock price?
Enliven Therapeutics, Inc. (ELVN) is currently trading at $16.87 per share. The stock has moved +1.14% today.
What is the analyst price target for ELVN?
The average analyst price target for ELVN is $45.50, based on 1 analyst.
What sector is Enliven Therapeutics, Inc. in?
Enliven Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ELVN's market cap?
Enliven Therapeutics, Inc. has a market capitalization of $1.00 billion, making it a small-cap company.
Does ELVN pay dividends?
No, Enliven Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
DNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
Explore stocks similar to ELVN for comparison